Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 01-06-2018 | Original Article

Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer’s disease

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 6/2018

Abstract

Purpose

We aimed to determine the amyloid (Aβ) and tau biomarker levels associated with imminent Alzheimer’s disease (AD) - related metabolic decline in cognitively normal individuals.

Methods

A threshold analysis was performed in 120 cognitively normal elderly individuals by modelling 2-year declines in brain glucose metabolism measured with [¹⁸F]fluorodeoxyglucose ([¹⁸F]FDG) as a function of [¹⁸F]florbetapir Aβ positron emission tomography (PET) and cerebrospinal fluid phosphorylated tau biomarker thresholds. Additionally, using a novel voxel-wise analytical framework, we determined the sample sizes needed to test an estimated 25% drugeffect with 80% of power on changes in FDG uptake over 2 years at every brain voxel.

Results

The combination of [¹⁸F]florbetapir standardized uptake value ratios and phosphorylated-tau levels more than one standard deviation higher than their respective thresholds for biomarker abnormality was the best predictor of metabolic decline in individuals with preclinical AD. We also found that a clinical trial using these thresholds would require as few as 100 individuals to test a 25% drug effect on AD-related metabolic decline over 2 years.

Conclusions

These results highlight the new concept that combined Aβ and tau thresholds can predict imminent neurodegeneration as an alternative framework with a high statistical power for testing the effect of disease-modifying therapies on [¹⁸F]FDG uptake decline over a typical 2-year clinical trial period in individuals with preclinical AD.

Available only for authorised users

Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12:292–323. https://doi.org/10.1016/j.jalz.2016.02.002.CrossRefPubMed

Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer's disease: implications for prevention trials. Neuron. 2014;84:608–22. https://doi.org/10.1016/j.neuron.2014.10.038.CrossRefPubMedPubMedCentral

Holland D, McEvoy LK, Desikan RS, Dale AM; Alzheimer's Disease Neuroimaging Initiative. Enrichment and stratification for predementia Alzheimer disease clinical trials. PLoS One. 2012;7:e47739. https://doi.org/10.1371/journal.pone.0047739.CrossRefPubMedPubMedCentral

Gauthier S, Albert M, Fox N, Goedert M, Kivipelto M, Mestre-Ferrandiz J, et al. Why has therapy development for dementia failed in the last two decades? Alzheimers Dement. 2016;12:60–4. https://doi.org/10.1016/j.jalz.2015.12.003.CrossRefPubMed

Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280–92. https://doi.org/10.1016/j.jalz.2011.03.003.CrossRefPubMedPubMedCentral

Fouquet M, Desgranges B, Landeau B, Duchesnay E, Mezenge F, de la Sayette V, et al. Longitudinal brain metabolic changes from amnestic mild cognitive impairment to Alzheimer's disease. Brain. 2009;132:2058–67. https://doi.org/10.1093/brain/awp132.CrossRefPubMedPubMedCentral

Jagust W, Reed B, Mungas D, Ellis W, Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology. 2007;69:871–7. https://doi.org/10.1212/01.wnl.0000269790.05105.16.CrossRefPubMed

Torosyan N, Mason K, Dahlbom M, Silverman DHS; Alzheimer’s Disease Neuroimaging Initiative. Value of FDG-PET scans of non-demented patients in predicting rates of future cognitive and functional decline. Eur J Nucl Med Mol Imaging. 2017;44:1355–63. https://doi.org/10.1007/s00259-017-3634-3.CrossRefPubMed

Morbelli S, Bauckneht M, Arnaldi D, Picco A, Pardini M, Brugnolo A, et al. 18F-FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer's disease (AD) patients at the mild cognitive impairment (MCI) stage. Eur J Nucl Med Mol Imaging. 2017;44:2073–83; https://doi.org/10.1007/s00259-017-3790-5.CrossRefPubMed

10.

Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology. 2007;68:501–8. https://doi.org/10.1212/01.wnl.0000244749.20056.d4.CrossRefPubMed

11.

Bruck A, Virta JR, Koivunen J, Koikkalainen J, Scheinin NM, Helenius H, et al. [11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment. Eur J Nucl Med Mol Imaging. 2013;40:1567–72. https://doi.org/10.1007/s00259-013-2478-8.CrossRefPubMed

12.

Duyckaerts C. Tau pathology in children and young adults: can you still be unconditionally baptist? Acta Neuropathol. 2011;121:145–7. https://doi.org/10.1007/s00401-010-0794-7.CrossRefPubMed

13.

Pascoal TA, Mathotaarachchi S, Mohades S, Benedet AL, Chung CO, Shin M, et al. Amyloid-beta and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease. Mol Psychiatry. 2017;22:306–11. https://doi.org/10.1038/mp.2016.37.CrossRefPubMed

14.

Pascoal TA, Mathotaarachchi S, Shin M, Benedet AL, Mohades S, Wang S, et al. Synergistic interaction between amyloid and tau predicts the progression to dementia. Alzheimers Dement. 2017;13:644–53. https://doi.org/10.1016/j.jalz.2016.11.005.CrossRefPubMed

15.

Toledo JB, Xie SX, Trojanowski JQ, Shaw LM. Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI. Acta Neuropathol. 2013;126:659–70. https://doi.org/10.1007/s00401-013-1151-4.CrossRefPubMed

16.

Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects. Ann Neurol. 2009;65:403–13. https://doi.org/10.1002/ana.21610.CrossRefPubMedPubMedCentral

17.

Eskildsen SF, Coupe P, Fonov V, Manjon JV, Leung KK, Guizard N, et al. BEaST: brain extraction based on nonlocal segmentation technique. Neuroimage. 2012;59:2362–73. https://doi.org/10.1016/j.neuroimage.2011.09.012.CrossRefPubMed

18.

Zijdenbos AP, Forghani R, Evans AC. Automatic "pipeline" analysis of 3-D MRI data for clinical trials: application to multiple sclerosis. IEEE Trans Med Imaging. 2002;21:1280–91. https://doi.org/10.1109/TMI.2002.806283.CrossRefPubMed

19.

Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72:578–86. https://doi.org/10.1002/ana.23650.CrossRefPubMedPubMedCentral

20.

Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, et al. Performance characteristics of amyloid PET with florbetapir F18 in patients with Alzheimer's disease and cognitively normal subjects. J Nucl Med. 2012;53:378–84. https://doi.org/10.2967/jnumed.111.090340.CrossRefPubMed

21.

Mazziotta J, Toga A, Evans A, Fox P, Lancaster J, Zilles K, et al. A probabilistic atlas and reference system for the human brain: international consortium for brain mapping (ICBM). Philos Trans R Soc Lond B Biol Sci. 2001;356:1293–322. https://doi.org/10.1098/rstb.2001.0915.CrossRefPubMedPubMedCentral

22.

Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207–16. https://doi.org/10.1016/S1474-4422(12)70291-0.CrossRefPubMedPubMedCentral

23.

Mathotaarachchi S, Wang S, Shin M, Pascoal TA, Benedet AL, Kang MS, et al. VoxelStats: a MATLAB package for multi-modal voxel-wise brain image analysis. Front Neuroinform. 2016;10:20. https://doi.org/10.3389/fninf.2016.00020.CrossRefPubMedPubMedCentral

24.

Leung KK, Clarkson MJ, Bartlett JW, Clegg S, Jack CR Jr, Weiner MW, et al. Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: tissue-specific intensity normalization and parameter selection. Neuroimage. 2010;50:516–23. https://doi.org/10.1016/j.neuroimage.2009.12.059.CrossRefPubMed

25.

Grill JD, Di L, Lu PH, Lee C, Ringman J, Apostolova LG, et al. Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's disease Neuroimaging initiative. Neurobiol Aging. 2013;34:62–72. https://doi.org/10.1016/j.neurobiolaging.2012.03.006.CrossRefPubMed

26.

Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995;57:289–300.

27.

Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor MN. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol. 2000;57:339–44.CrossRefPubMed

28.

Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, Madison C, Ayakta N, Ghosh PM, et al. Existing Pittsburgh compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain. 2015;138:2020–33. https://doi.org/10.1093/brain/awv112.

29.

Kuhl DE, Metter EJ, Riege WH, Hawkins RA. The effect of normal aging on patterns of local cerebral glucose utilization. Ann Neurol. 1984;15(Suppl):S133–7.CrossRefPubMed

30.

Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Mandel F, Alexander GE, et al. The metabolic topography of normal aging. J Cereb Blood Flow Metab. 1996;16:385–98. https://doi.org/10.1097/00004647-199605000-00005.CrossRefPubMed

31.

Lowe VJ, Weigand SD, Senjem ML, Vemuri P, Jordan L, Kantarci K, et al. Association of hypometabolism and amyloid levels in aging, normal subjects. Neurology. 2014;82:1959–67. https://doi.org/10.1212/WNL.0000000000000467.CrossRefPubMedPubMedCentral

32.

Mosconi L, Mistur R, Switalski R, Brys M, Glodzik L, Rich K, et al. Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease. Neurology. 2009;72:513–20. https://doi.org/10.1212/01.wnl.0000333247.51383.43.CrossRefPubMedPubMedCentral

33.

Thal DR, Rub U, Orantes M, Braak H. Phases of a beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791–800.CrossRefPubMed

34.

Delacourte A, David JP, Sergeant N, Buee L, Wattez A, Vermersch P, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology. 1999;52:1158–65.CrossRefPubMed

35.

Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–59.CrossRefPubMed

36.

Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, et al. Independent information from cerebrospinal fluid amyloid-beta and florbetapir imaging in Alzheimer's disease. Brain. 2015;138:772–83. https://doi.org/10.1093/brain/awu367.CrossRefPubMed

Title: Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer’s disease
Publication date: 01-06-2018
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 6/2018
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-018-3933-3

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer’s disease

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2018

Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

68Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancer

Extraction, selection and comparison of features for an effective automated computer-aided diagnosis of Parkinson’s disease based on [123I]FP-CIT SPECT images

Ultra-early response assessment in lymphoma treatment: [18F]FDG PET/MR captures changes in glucose metabolism and cell density within the first 72 hours of treatment

Advantage of 18F-PSMA-1007 over 68Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion

PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer